AstraZeneca-Amgen Drug Achieves 69% Remission in Esophageal Disease Trial
Amgen and AstraZeneca said their asthma drug reduced swallowing difficulties and achieved disease remission in 69% of patients with a chronic inflammatory esophageal disorder.
Amgen (NASDAQ:AMGN) and AstraZeneca (LSE:AZN) said Tuesday that their asthma drug reduced swallowing difficulties and put 69% of patients with a type of chronic inflammatory esophageal disorder into remission. The finding adds to data reported in August, when AstraZeneca said the drug met the…